You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aminoglycosides with reduced ototoxicity via miRNA targeting
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a bioconjugate vaccine against Group B Streptococcus
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non-pregnant adults. GBS neonatal disease manifests as early onset, defined as disease within the first six days after birth, or late onset, defined as disease occurring after the f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE
SBC: Mitochondria in Motion, Inc. Topic: 999Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: There are a number of rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), for which there is no available or effective therapy and which lead to significant mor ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biologically Targeted Vaccine for Chikungunya
SBC: PRECISION VIROLOGICS INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution
SBC: SGgenomics, Inc. Topic: 101PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A New Small-Molecule Kinase Inhibitor for Airway Disease
SBC: NuPeak Therapeutics, Inc. Topic: NHLBIAbstract NuPeak Therapeutics Incis a biotechnology companyC corporationdesigned to deliver a first in class smallmolecule kinase inhibitorSMKIfor therapeutic use in humansThe present Project is aimed at an inhibitor for treatment of respiratory airway disease especially due to asthma and COPDwhich remain leading causes of morbidity and mortality in the U Sand worldwide despite current therapeutic ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy
SBC: Medical Guidance Systems LLC Topic: 102Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury
SBC: Lydex Pharmaceuticals LLC Topic: 300Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation
SBC: NEWVENTUREIQ LLC Topic: NIAIDABSTRACT Human leukocyte antigenHLAtyping is an essential laboratory test to evaluate the donor recipient compatibility before life saving transplantationsInaloneHLA typing of donors and recipients guided overorgan and stem cell transplantations in the United StatesExisting high resolution HLA typing methods require a turnaround time of days to weeksThere has been an unmet clinical need for a rapi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health